Literature DB >> 8334588

Pathophysiology of cerebellar dysfunction in the Wernicke-Korsakoff syndrome.

R F Butterworth1.   

Abstract

Cerebellar ataxia is a common presenting sign in the Wernicke-Korsakoff syndrome (WKS). Recovery from ataxia following thiamine treatment is rarely complete, suggesting the existence of both a reversible ("biochemical") lesion as well as irreversible, neuropathological damage. Cerebellar pathology in WKS includes severe loss of Purkinje cells in superior cerebellar vermis as well as neuronal loss from the granular layer. In addition, damage to inferior olivary nucleus could result in loss of climbing fibre input to cerebellum in this condition. Experiments using an animal model of WKS, the pyrithiamine-treated rat, reveal selective reversible decreases of alpha-ketoglutarate dehydrogenase (alpha KGDH) in cerebellum. Decreased enzyme activities are associated with decreased cerebellar content of GABA and aspartate. Thiamine reversal of neurological symptoms results in normalization of cerebellar enzyme activities and GABA content suggesting that reduced activities of alpha KGDH constitute "the biochemical lesion" in these animals. Possible mechanisms implicated in neuronal cell death in cerebellum include impaired cellular energy metabolism, focal lactic acidosis and excitotoxic damage resulting from excess glutamate release mediated by N-methyl-D-aspartate (NMDA) receptors. Similar mechanisms could be involved in the reversible and irreversible neurological symptoms of WKS in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8334588

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  12 in total

1.  Home-based behavioral treatment.

Authors:  K Pomeranz
Journal:  J Autism Dev Disord       Date:  1999-10

Review 2.  The current state of S. S. Korsakov's concept of alcoholic polyneuritic psychosis.

Authors:  Yu P Sivolap
Journal:  Neurosci Behav Physiol       Date:  2005-11

3.  Odorant-induced and sniff-induced activation in the cerebellum of the human.

Authors:  N Sobel; V Prabhakaran; C A Hartley; J E Desmond; Z Zhao; G H Glover; J D Gabrieli; E V Sullivan
Journal:  J Neurosci       Date:  1998-11-01       Impact factor: 6.167

Review 4.  Neurological complications post-liver transplantation: impact of nutritional status.

Authors:  Chantal Bemeur
Journal:  Metab Brain Dis       Date:  2012-11-06       Impact factor: 3.584

5.  Vermal atrophy of alcoholics correlate with serum thiamine levels but not with dentate iron concentrations as estimated by MRI.

Authors:  Matthias Maschke; Johannes Weber; Udo Bonnet; Albena Dimitrova; Julia Bohrenkämper; Sonja Sturm; Bernhard W Müller; Markus Gastpar; Hans-Christopher Diener; Michael Forsting; Dagmar Timmann
Journal:  J Neurol       Date:  2005-03-23       Impact factor: 4.849

Review 6.  Brain and behavioral pathology in an animal model of Wernicke's encephalopathy and Wernicke-Korsakoff Syndrome.

Authors:  Ryan P Vetreno; Raddy L Ramos; Steven Anzalone; Lisa M Savage
Journal:  Brain Res       Date:  2011-11-28       Impact factor: 3.252

7.  A case of probable korsakoff's syndrome: a syndrome of frontal lobe and diencephalic structural pathogenesis and a comparison with medial temporal lobe dementias.

Authors:  David R Spiegel; Kheng-Jim Lim
Journal:  Innov Clin Neurosci       Date:  2011-06

8.  Thiamine Deficiency Increases Ca2+ Current and CaV1.2 L-type Ca2+ Channel Levels in Cerebellum Granular Neurons.

Authors:  Daniel C Moreira-Lobo; Jader S Cruz; Flavia R Silva; Fabíola M Ribeiro; Christopher Kushmerick; Fernando A Oliveira
Journal:  Cell Mol Neurobiol       Date:  2016-05-02       Impact factor: 5.046

Review 9.  Susceptibility of the cerebellum to thiamine deficiency.

Authors:  Patrick J Mulholland
Journal:  Cerebellum       Date:  2006       Impact factor: 3.648

10.  Dysautonomia, a heuristic approach to a revised model for etiology of disease.

Authors:  Derrick Lonsdale
Journal:  Evid Based Complement Alternat Med       Date:  2007-07-13       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.